Kilitch Drugs vs Sudarshan Pharma vs Chandan Healthcare: Which Stock Should You Track
- October 13, 2026
- Posted by: Neeraj Pandey
- Category: Market
Kilitch Drugs (India) PE 29.19, mkt cap Rs 852 crore. Sudarshan Pharma Industries PE 35.15, mkt cap Rs 878 crore. Chandan Healthcare PE 23.06, mkt cap Rs 581 crore.
Quick Answer
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Kilitch Drugs (India) carries a market capitalisation of about Rs 852 crore, against Rs 878 crore for Sudarshan Pharma Industries and Rs 581 crore for Chandan Healthcare, with return on equity of 10.79%, 15.03% and 11.34% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare: Company Overview
Kilitch Drugs (India) is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 852 crore, a return on equity of 10.79% and a book value of Rs 79.99 per share. Its quarterly revenue moved from Rs 45.70 crore in June 2025 to Rs 47.78 crore in June 2026, a change of +4.6%.
Sudarshan Pharma Industries is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 878 crore, a return on equity of 15.03% and a book value of Rs 6.67 per share. Its quarterly revenue moved from Rs 146.47 crore in June 2025 to Rs 175.64 crore in June 2026, a change of +19.9%.
Chandan Healthcare is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 581 crore, a return on equity of 11.34% and a book value of Rs 69.48 per share. Its quarterly revenue moved from Rs 68.77 crore in June 2025 to Rs 82.26 crore in June 2026, a change of +19.6%.
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Valuation and Profitability Snapshot
| Metric | Kilitch Drugs (India) | Sudarshan Pharma Industries | Chandan Healthcare |
|---|---|---|---|
| Market Cap (approx.) | Rs 852 crore | Rs 878 crore | Rs 581 crore |
| PE Ratio (TTM) | 29.19 | 35.15 | 23.06 |
| PB Ratio | 3.05 | 5.27 | 3.42 |
| Return on Equity (ROE) | 10.79% | 15.03% | 11.34% |
| EPS (TTM, Rs) | 8.35 | 1.00 | 10.30 |
| Dividend Yield | 0.00% | 0.00% | 0.00% |
| Debt to Equity | 0.32 | 1.84 | 0.31 |
| Book Value per Share (Rs) | 79.99 | 6.67 | 69.48 |
Check the Univest Screener for Live Data
On valuation, Kilitch Drugs (India) trades at a PE of 29.19 and a PB of 3.05, Sudarshan Pharma Industries at a PE of 35.15 and a PB of 5.27, while Chandan Healthcare trades at a PE of 23.06 and a PB of 3.42. On return on equity, the three post 10.79%, 15.03% and 11.34% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.00%. Sudarshan Pharma Industries has the highest market capitalisation of the three at Rs 878 crore, while Chandan Healthcare has the lowest at Rs 581 crore. Sudarshan Pharma Industries has the highest PE ratio of the three at 35.15, while Chandan Healthcare has the lowest at 23.06. Sudarshan Pharma Industries has the highest return on equity of the three at 15.03%, while Kilitch Drugs (India) has the lowest at 10.79%. Sudarshan Pharma Industries has the highest debt to equity ratio of the three at 1.84, while Chandan Healthcare has the lowest at 0.31. Debt to equity is 0.32, 1.84 and 0.31 for the three respectively.
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Kilitch Drugs (India) | Rs 47.78 crore | Rs 1.97 crore | +4.6% | -47.0% | -12.8% |
| Sudarshan Pharma Industries | Rs 175.64 crore | Rs 5.61 crore | +19.9% | -22.0% | +41.7% |
| Chandan Healthcare | Rs 82.26 crore | Rs 7.91 crore | +19.6% | +6.2% | +28.0% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Kilitch Drugs (India) | Sudarshan Pharma Industries | Chandan Healthcare |
|---|---|---|---|
| June 2025 | Rs 45.70 crore | Rs 146.47 crore | Rs 68.77 crore |
| September 2025 | Rs 55.58 crore | Rs 170.73 crore | Rs 68.74 crore |
| December 2025 | Rs 55.34 crore | Rs 169.53 crore | Rs 65.78 crore |
| March 2026 | Rs 90.09 crore | Rs 225.05 crore | Rs 77.43 crore |
| June 2026 | Rs 47.78 crore | Rs 175.64 crore | Rs 82.26 crore |
Quarterly net profit (Rs crore)
| Quarter | Kilitch Drugs (India) | Sudarshan Pharma Industries | Chandan Healthcare |
|---|---|---|---|
| June 2025 | Rs 2.26 crore | Rs 3.96 crore | Rs 6.18 crore |
| September 2025 | Rs 8.04 crore | Rs 3.87 crore | Rs 8.25 crore |
| December 2025 | Rs 4.32 crore | Rs 4.15 crore | Rs 5.03 crore |
| March 2026 | Rs 14.88 crore | Rs 11.39 crore | Rs 4.94 crore |
| June 2026 | Rs 1.97 crore | Rs 5.61 crore | Rs 7.91 crore |
Kilitch Drugs (India) reported revenue of Rs 45.70 crore in June 2025 and Rs 47.78 crore in June 2026, a change of +4.6% across the period. Its highest quarterly revenue in this window was Rs 90.09 crore in March 2026. Net profit stood at Rs 1.97 crore in June 2026, which is a net profit margin of 4.12%.
Sudarshan Pharma Industries reported revenue of Rs 146.47 crore in June 2025 and Rs 175.64 crore in June 2026, a change of +19.9% across the period. Its highest quarterly revenue in this window was Rs 225.05 crore in March 2026. Net profit stood at Rs 5.61 crore in June 2026, which is a net profit margin of 3.19%.
Chandan Healthcare reported revenue of Rs 68.77 crore in June 2025 and Rs 82.26 crore in June 2026, a change of +19.6% across the period. Its highest quarterly revenue in this window was Rs 82.26 crore in June 2026. Net profit stood at Rs 7.91 crore in June 2026, which is a net profit margin of 9.62%.
Download the Univest iOS App or Univest Android App to track Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and working capital needs. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Kilitch Drugs (India) vs Sudarshan Pharma Industries vs Chandan Healthcare
What is the market cap difference between Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?
Ans. As of October 2026, Kilitch Drugs (India) has a market cap of approximately Rs 852 crore, Sudarshan Pharma Industries is at approximately Rs 878 crore, and Chandan Healthcare is at approximately Rs 581 crore.
What are the PE and PB ratios of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?
Ans. As of October 2026, the PE ratios stand at 29.19, 35.15 and 23.06 respectively, and the price to book ratios stand at 3.05, 5.27 and 3.42 respectively.
Which of the three has the highest ROE?
Ans. Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare post ROE of 10.79%, 15.03% and 11.34% respectively as of October 2026. Sudarshan Pharma Industries has the highest return on equity of the three at 15.03%, while Kilitch Drugs (India) has the lowest at 10.79%.
Which of these three stocks pays the highest dividend yield?
Ans. Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare carry dividend yields of 0.00%, 0.00% and 0.00% respectively.
What is the debt to equity ratio for Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?
Ans. Kilitch Drugs (India) carries a debt to equity of 0.32, Sudarshan Pharma Industries of 1.84, and Chandan Healthcare of 0.31.
What were the latest quarterly revenue and net profit of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?
Ans. For Q1 FY27 (quarter ended June 2026), Kilitch Drugs (India) reported revenue of Rs 47.78 crore and net profit of Rs 1.97 crore, Sudarshan Pharma Industries reported revenue of Rs 175.64 crore and net profit of Rs 5.61 crore, and Chandan Healthcare reported revenue of Rs 82.26 crore and net profit of Rs 7.91 crore.
Does this comparison recommend one of Kilitch Drugs (India), Sudarshan Pharma Industries and Chandan Healthcare?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
